Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)

(2009) Barbara C. Baudner et al.   PHARMACEUTICAL RESEARCH

Cross-Talk between TLR4 and FcγReceptorIII (CD16) Pathways

(2009) Daniel Rittirsch et al.   PLoS Pathogens

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD

Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma

(2008) Y. M. Saenger et al.   CANCER RESEARCH

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

(2008) L. M. Weiner et al.   CLINICAL CANCER RESEARCH

Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs

(2008) Peter S. Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

(2008) Andrew L. Gilman et al.   JOURNAL OF CLINICAL ONCOLOGY